Iksuda to Present First Clinical Data for IKS03 at ASH
Iksuda says it will present first clinical data for IKS03 in advanced B-cell non-Hodgkin lymphomas at ASH. The body fragment claims early anti-tumour activity and a therapy-leading safety profile in heavily pretreated patients.